Herbst Kinsky has advised PhagoMed Biopharma's shareholders on the sale of the company to BioNTech.
As a result of the transaction, the acquired company has been renamed BioNTech R&D (Austria).
Founded in 2008, BioNTech is a German company specializing in patient-specific immunotherapies. The company’s suite of platforms includes mRNA therapeutics, engineered cell therapies, antibodies, and small molecule immunomodulators.
PhagoMed is an Austrian biotechnology company specializing in the development of a new class of antibacterials.
"Antimicrobial resistance (AMR) remains an urgent global threat and, as a society, we desperately need novel and more precise drugs," former PhagoMed CEO Alexander Belcredi commented. "We’re proud that we can now continue our fight against AMR as part of BioNTech, for the benefit of millions of patients."
The Herbst Kinsky team was led by Partner Christoph Wildmoser.
Herbst Kinsky did not respond to our inquiry on the matter.